Zevra Therapeutics, Inc. - Common Stock (ZVRA)

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results.

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic Metabolic Diseases Advisory Committee.